Pfizer nets first AIDS patent in India

Pfizer cleared a big milestone in India today: The company became the first to get patent protection for an AIDS drug there. The new patent covers Celzentry, or maraviroc, a new, first-in-class HIV remedy that was approved by the U.S. FDA in August.

Pfizer's victory follows several other attempts, including GlaxoSmithKline's bid for a patent on Combivir; opposition from patient groups prompted GSK to withdraw its application last year.

- read the report from the Economic Times
- see this chart of HIV drug patent applications and their status in the Business Standard

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.